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Background: This study characterizes the second hit spectrum in BRCA1 and BRCA2-associated breast
and ovarian cancers at both gene loci to investigate if second hit mechanisms are mutually exclusive or
able to coincide within the same tumor.
Methods: Loss of heterozygosity, somatic point mutations and copy number alterations along with
promoter methylation were studied in 56 breast and 15 ovarian cancers from BRCA1 and BRCA2
germline mutation carriers. A mathematical methodology was introduced to quantify the tumor cell
population carrying a second hit.
Results: Copy neutral LOH was the most prevalent LOH mechanism in this cohort (BC 69%, OC 67%).
However, only 36% of BC and 47% of OC showed LOH in all cancerous cells. Somatic intragenic deletions
and methylated subclones were also found in combination with (partial) loss of heterozygosity. Un-
equivocal deleterious somatic point mutations were not identiﬁed in this cohort.
Conclusion: Different mechanisms inactivating the wild type allele are present within the same tumor
sample at various extents. Results indicate that BRCA1/2-linked breast and ovarian cancer cells are
predominantly characterized by LOH, but harbor a complex combination of second hits at various
frequencies.
© 2018 Elsevier B.V. All rights reserved.ics Ghent, Medical Research
.
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Germline mutations in the tumor suppressor genes BRCA1 and
BRCA2 increase the lifetime risk (until the age of 80) of developing
breast cancer (BC) up to 72% (BRCA1) or 69% (BRCA2) and the risk for
ovarian cancer (OC) to 44% (BRCA1) or 17% (BRCA2) [1]. These genes
theoretically operate under Knudson's second hit hypothesis,
meaning that both alleles need to be inactivated to render the cell
vulnerable to genomic instability and irregular growth. In women
with a germline mutation, the risk of breast and ovarian cancer is
higher due to constitutional inactivation of one allele in all cells of
Abbreviations
BC breast cancer
BRCA1 and 2 breast cancer susceptibility gene 1 and 2
bVAF variant allele frequency for a variant in the germline
DNA sample derived from blood
CNA copy number alterations
cVAF variant allele frequency of a variant within a
cancerous cell showing loss of an allele
ENIGMA evidence-based network for the interpretation of
germline mutant alleles
ER estrogen receptor
FFPE formalin-ﬁxed parafﬁn embedded
HBOC hereditary breast and ovarian cancer
HE hematoxylin and eosin
HER2/Neu human epidermal growth factor receptor 2
HGSC high-grade serous carcinoma
IDC invasive ductal carcinoma
ILC invasive lobular carcinoma
Lc percentage of tumor cells in a sample that have loss
of heterozygosity
Lm percentage of tumor cells in a sample where an allele
is deleted
LOH loss of heterozygosity
mCN mean copy number of a gene as measured with MLPA
metR methylation rate; percentage of tumor cells where a
certain CpG is methylated
MLPA multiplex ligation-dependent probe ampliﬁcation
MNV multiple nucleotide variation
MPS massive parallel sequencing
MS-MLPA methylation-speciﬁc multiplex ligation-dependent
probe ampliﬁcation
NACT neoadjuvant chemotherapy
OC ovarian cancer
PR progesterone receptor
ROI region of interest
SNP single-nucleotide polymorphism
SNV single nucleotide variation
TCGA The Cancer Genome Atlas
TCP tumor cell percentage
TSG tumor suppressor gene
tVAF variant allele frequency for a variant in the tumor
DNA sample derived from formalin-ﬁxed parafﬁn
embedded tissue
UTR untranslated region
VAF variant allele frequency (describes the percentage of
reads containing the non-reference base pair
sequence); WT, wild type
M. Van Heetvelde et al. / Cancer Letters 425 (2018) 125e133126the body. A second somatic event may occur through either of three
mechanisms: 1) loss of heterozygosity (LOH), 2) the occurrence of a
pathogenic point mutation arising at the functional allele and 3)
epigenetic alterations, like promoter hypermethylation. The most
studied somatic event leading to the inactivation of the remaining
wild type (WT) allele is LOH due to large deletions, genomic rear-
rangements, incorrect mitosis or faulty DNA repair. Reports on LOH
in hereditary breast cancer date back as early as the discovery of
these two genes [2e4]. Somatic inactivating point mutations have
been described in a small minority of BRCA1 and BRCA2-associated
breast [5] and BRCA1-associated ovarian cancer cases [6]. Finally,
data on hypermethylation of the promoter region in germline
mutated tumors are scarce, but occurrences have been reported for
both genes [7,8].
Understanding the driver events for each tumor and subsequent
alterations guides the application of targeted therapy and person-
alized medicine in cancer. Yet the number of studies investigating
the combination of all 3 s hit mechanisms in BRCA1 and BRCA2 is
limited. This study aims to investigate the prevalence of LOH, point
mutations, and methylation, in a cohort of breast and ovarian tu-
mors from patients with a germline BRCA1 or BRCA2 mutation.
Taking tumor cell percentages into account, we developed a
mathematical methodology to depict a detailed landscape of so-
matic events combining data generated by massive parallel
sequencing (MPS), multiplex ligation-dependent probe ampliﬁca-
tion (MLPA) and methylation-speciﬁc MLPA (MS-MLPA).2. Materials and methods
2.1. Patient cohort
Formalin-ﬁxed parafﬁn embedded (FFPE) tissue of 127 primary
breast tumors and ﬁfteen primary ovarian tumors, resected from
patients with a germline BRCA1 or BRCA2 mutation, were collected
from Ghent University Hospital, AZ St.-Jan Bruges-Ostend and AZ
Delta Roeselare. A DNA sample extracted from EDTA blood andrelevant clinical information was available. Fig. 1 provides a ﬂow-
chart of the patient material and methodologies applied.
2.2. Sample preparation
FFPE samples were sectioned (5 mm), ﬁxed on 1.0 PEN slides
(Carl Zeiss Microscopy, Cambridge, UK) and stained with hema-
toxylin and eosin (HE) according to Liu et al. [9] Three consecutive
sections were used for DNA extraction after laser-guided macro-
dissection on PALMMicrobeam equipment (Carl Zeiss Microscopy),
using QIAampMicro DNA kits (Qiagen, Hilden, Germany) according
to manufacturer's protocol. Only 88 breast samples yielded sufﬁ-
cient amounts (>125 ng total DNA) and quality (>1.5 absorbance
260/280 nm) of DNA as measured by ﬂuorimetry (Qubit 1.0;
Thermo Scientiﬁc Fisher, Waltham, USA) and spectrophotometry
(DropSense96, Trinean, Ghent, Belgium) and were included in the
study. All 15 ovarian samples were included.
2.3. Sequencing of the BRCA1 and BRCA2 coding regions
The entire coding regions of both BRCA1 and BRCA2 and twenty
ﬂanking nucleotides (region of interest, ROI) were ampliﬁed and
sequenced in DNA extracted from 103 tumor samples and the
corresponding blood samples using multiplex PCR (Supplementary
Methods). We always investigated both loci, independent of the
locus of the germline mutation. Thirty-two BC tumor samples
yielded too low coverage for adequate analysis, probably due to the
age of the FFPE material (Supplementary Fig. 1) and were excluded
for further analyses. Reliable sequencing results were obtained for
56 BC and 15 OC cases.
2.4. Pathology assessment
BC subtype was determined, and tumors were graded according
to the Elston-Ellis modiﬁcation of the Scarff-Bloom-Richardson
grading system [10]. Two pathologists, scored independently
Fig. 1. Flowchart to clarify the methodology followed in the study.
The grey boxes explain each step in the workﬂow as described in detail in the ‘Materials and methods’ section. The arrows link the different steps in the procedure. Orange boxes
describe the criteria to include a sample in speciﬁc steps of the workﬂow.
Table 1
Summary of somatic variants found in breast cancer samples.
BRCA1 n¼ 105 (%)* BRCA2 n¼ 164 (%)*
Sequence change C:G> T:A 91 (86.7) 131 (79.9)
T:A> C:G 9 (8.6) 22 (13.4)
other SNV 4 (3.8) 11 (6.7)
MNV 1 (1.0) 0 (0)
Gene location 50 UTR 0 (0) 3 (1.8)
exon 101 (96.2) 160 (97.6)
intron 4 (3.8) 0 (0)
splice site 0 (0) 1 (0.6)
SNV¼ single nucleotide variation.
MNV¼multiple nucleotide variation.
UTR¼ untranslated region.
* Gene in which variants were detected.
M. Van Heetvelde et al. / Cancer Letters 425 (2018) 125e133 127tumor cell percentages (TCP) on one HE slide per sample and the
mean of both scores was taken. The mean discordance between
scores was 8± 2%. The sections scoredwere adjacent to the sections
used for DNA extraction. Immunohistochemistry for the estrogen
receptor (ER), progesterone receptor (PR) and Ki-67 and Human
Epidermal Growth Factor Receptor 2 (HER2/Neu) was performed
using 3.5 mm FFPE tissue sections, as previously described [11,12].
Fluorescence-in-situ hybridization was applied to determine the
HER2/Neu ampliﬁcation status in breast tumors with an equivocal
(2þ) HER2/Neu score by immunohistochemistry, according to an
established protocol [11]. Supplementary Fig. 2 contains images of
immunohistochemistry, while Supplementary Table 1 provides a
summary of the histopathological features of all samples included
in the study.
2.5. Copy number analysis
For detection of exon-spanning deletions/ampliﬁcations we
used SALSA MLPA P002-D1 BRCA1 and SALSA MLPA P045-B3
BRCA2/CHEK2 probemixes (MRC-Holland, Amsterdam, the
Netherlands). We always performed MLPA for both loci, indepen-
dent of the locus of the germline mutation. DNA samples from in-
dividuals with normal (n¼ 6) or aberrant (n¼ 4) MLPA proﬁles
were included in each experiment to test for inter-experimental
variability. Details on data processing and normalization can be
found in Supplementary Methods.
2.6. Methylation analysis
Methylation of the promoter regions of both genes was inves-
tigated with MS-MLPA (SALSA MLPA ME053-X1 BRCA1-BRCA2
probemix (MRC-Holland)) in accordance to manufacturer's rec-
ommendations and analyzed using Coffalyser.Net software (MRC-
Holland). The same control samples as in 2.5 were tested. In everyexperiment a no-template control, an unmethylated (Human
HCT116 DKO Non-methylated DNA, Zymo Research, Irvine, USA)
and methylated control (CpGenom Universal Methylated DNA,
EMD Millipore, Billerica, USA) were included. Methylation rates
(metR) (¼ percentage of tumor cells methylated at MS-MLPA probe
positions) were calculated by dividing the normalized probe ratio
by TCP. To evaluate the quantitative potential of the SALSA MLPA
ME053-X1 BRCA1-BRCA2 probemix, dilution series were made
from six artiﬁcial mixtures of the methylated and unmethylated
controls, corresponding to 0, 10, 20, 50, 75 or 100% methylation.3. Results
3.1. Somatic variants in the BRCA1 and BRCA2 coding regions
detected by sequencing
In 56 BC samples 269 somatic variants were retained. Table 1
shows the distribution of these variants. The ratio in which these
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ratio of number of bases in the ROI is 5759/10625 BRCA1/BRCA2
(54%). Thirty-seven of these variants occurred in BRCA2-associated
tumors (n¼ 20), while the BRCA1-associated cancers (n¼ 36)
harbored 232 variants. Themajority (177/269) of the variants found
were missense variants and concerned C:G> T:A substitutions,
indicative for ﬁxation artefacts. In the ovarian cancers (n¼ 15) we
found one benign somatic variant, NM_007294.3:c.4146C> T
(p.Cys1382¼ ; with VAF (percentage of reads containing the non-
reference base pair sequence)¼ 23.74%).
3.2. Somatic intragenic copy number alterations in BRCA1 and
BRCA2 detected by MLPA
We performed MLPA to investigate if exon-spanning deletions/
ampliﬁcations in BRCA1 or BRCA2 occur at the somatic level. Fig. 2
shows heatmaps of the intragenic copy number data. Several
samples (Table 2.1) showed signs of somatic exon-spanning de-
letions in BRCA1 and/or BRCA2 and in several OC samples there was
consistent somatic loss of the ﬁrst exon of BRCA2 (independent of
the locus of the germlinemutation). For two BCs from patients with
a deletion spanning several exons at the germline level, BC_29
(NM_000059.3:c.8332-?_8487þ?del) and BC_55
(NM_007294.3:c.5075-?_5193þ?del) low ratios for the germline
deleted exons were suggestive for partial loss of the WT allele.
3.3. Establishment of a method to quantify the percentage of tumor
cells showing loss/inactivation of the wild type allele
LOH was calculated taking into account three variables; 1) TCP,
2) the VAFs of the germline mutation and heterozygous SNPs (if
present) in the blood sample (bVAF) and 3) corresponding VAFs for
the same variants in the matching tumor sample (tVAF). tVAF is
entirely dependent on TCP and the percentage of tumor cells
exhibiting loss of the WT or mutant allele (Lc). Mathematically this
is can be described as formula 1. cVAF is a theoretical value, namely
the VAF of a single tumor cell that exhibits loss of one of the alleles.
This cVAF can be either 0 (the allele containing the non-reference
sequence is lost, meaning tVAF for the non-reference sequence
reads <50%) or 1 (the WT allele is lost, tVAF non-reference
sequence reads >50%). From formula 1, the Lc (percentage of tu-
mor cells showing LOH) can be derived (formula 2). This equation is
used to calculate an Lc value for each variant separately (presented
as boxplots in Fig. 3). The overall Lc value for each gene was
determined as the median of all Lc values (Supplementary Table 2).
Using the normalized MLPA data, the mean number of copies
(mCN) was determined by dividing the value for each MLPA probe
by themean of the reference probes in the respectiveMLPA kits and
taking the mean of the results. The percentage of tumor cells
exhibiting LOH due to physical loss of one allele (Lm) was then
calculated using formula 3. Both Lc and Lm represent a percentage
of tumor cells with a genomic aberration. Lm/Lc gives the per-
centage of cells with LOH through physical loss of an allele out of all
cells displaying LOH. Supplementary Fig. 3 clariﬁes these calcula-
tions with a hypothetical sample.
tVAF ¼ ð1 TCPÞbVAF þ TCP$ð½1 Lc$bVAF þ Lc$cVAFÞ (1)Fig. 2. Results of intragenic copy number analysis. a) Results obtained by the MLPA kit contai
Each color contains a different subset of samples. Samples ordered in the same way as in Su
Data used for the heatmaps can be seen in Supplementary Table 4. Probe details can be fou
P045-B3 BRCA2/CHEK2 probemixes (www.MLPA.com). Heatmaps were created using ‘heat
tograms for MLPA ratios. The light blue line shows the number of copies in function of thepercentage of tumor cells that exhibit LOH ¼ Lc
¼ tVAF  bVAF
TCP$cVAF  bVAF$TCP (2)
percentage of tumor cells with physical allelic loss ¼ Lm
¼ 2 2$mCN
TCP
(3)
3.4. Integrated analysis of loss of heterozygosity based on
sequencing and MLPA data
LOHwas calculated for all samples through formula 1-3. Data for
Lc and Lm calculations for both genes can be found in Fig. 3.
Detailed information on every individual sample can be retrieved
from Supplementary Table 2 and Table 2.2 provides a summary of
these data. In our cohort copy neutral LOH turned out to be the
most predominant mechanism. Remarkably, several BRCA1-asso-
ciated BC and OC samples showed allelic loss in BRCA2 and, simi-
larly, several BRCA2-associated tumor samples displayed allelic loss
in BRCA1. Fig. 3 shows a large number of samples with a discrep-
ancy between the percentage of tumor cells with LOH (Lc) and the
percentage of tumor cells where an allele was deleted (Lm).
Possibly these samples contain more than one subclone with
different copy numbers and heterozygosity.
3.5. Somatic methylation of BRCA1 and BRCA2 promoter regions
detected by MS-MLPA
Using MS-MLPA the methylation status of the promoter region
of BRCA1 and BRCA2was examined (probe details in Supplementary
Table 3). No interpretable data could be obtained for BC_01, BC_02,
BC_22, BC_29 and OC_15. Supplementary Fig. 4a shows the results
of the control samples. MS-MLPA is suggested to be quantitative
[13]. We evaluated this by including a dilution series containing
different amounts of the methylated and unmethylated controls.
Linear regression showed a coefﬁcient of determination close to 1,
indicating reliable quantiﬁcation for this artiﬁcial sample series
(Supplementary Fig. 4b). Consequently, the probe signals detected
in BC and OC samples were used to calculate the number of tumor
cells that exhibit methylation at a speciﬁc CpG site (methylation
rate, metR). We found a high degree of variability between probes,
but for most samples metR was <20% (Fig. 4). For two probes >20%
of tumor cells were methylated in a large number of BC samples
(63% for BRCA1.2 and 75% for BRCA2.1). For ovarian cancers this was
14% and 21% for each probe respectively. Methylation rates for
BRCA1.2 and BRCA2.1 probe targets were higher in the majority of
samples compared to other CpGs. The correlation between BRCA1.2
and BRCA2.1 was better (tau¼ 0.65 and p-value¼ 3.5e-14, CpGs
located on different chromosomes) than probe targets surrounding
them in the promoter region of the same gene. Correlation for
BRCA2.1 and BRCA2.2, separated by 215 bp, resulted in tau¼ 0.59
and p¼ 7.4e-12.
4. Discussion
The objective of this study was to paint a detailed picture ofning probes for BRCA1. b) Legend to interpret the row colors at the left of the heatmaps.
pplementary Table 2. c) Results obtained by the MLPA kit containing probes for BRCA2.
nd in the online documentation of the SALSA MLPA P002-D1 BRCA1 and SALSA MLPA
map.2’ function of the R package ‘gplots’. In the top right corner of a) and c) are his-
number of target probes.
Table 2
Overview of copy number and LOH data.
BRCA1 carrier BRCA2 carrier
BC n¼ 36 (%) OC n¼ 9 (%) BC n¼ 20 (%) OC n¼ 6 (%)
2.1 Intragenic copy number alterations
BRCA1 exon(s) lossa 7 (19) 5 (56) 6 (30) 3 (50)
BRCA2 exon(s) lossa 4 (11) 1 (11) 1 (5) 2 (33)
2.2 Gene-wide copy number alterations
LOH in all cells 16 (44) 4 (44) 4 (20) 3 (50)
LOH in >50% of cells 29 (80) 8 (88) 8 (40) 6 (100)
no LOH in >50% of cells 7 (19) 1 (11) 4 (20) 0 (0)
copy neutral LOHb 28 (78) 6 (67) 3 (15) 4 (67)
LOH by deleterious eventb 6 (17) 2 (22) 8 (40) 1 (17)
a Samples expected to have one or more exon-spanning deletion in this gene.
b Counting only samples for which interpretable data for both MLPA and sequencing were available.
Fig. 3. Integrated LOH analysis using both sequencing and MLPA data.
Boxplots represent Lc values (percentage of tumor cells in a sample that show LOH) for all germline heterozygous markers found in each sample as determined by sequencing. No
correction was done on Lc values, as it is impossible to tell which factor (tVAF, bVAF or TCP) was responsible for the over- or underestimation of Lc. BRCA1 and BRCA2 are depicted in
the upper and lower plots respectively. Samples with an asterisk indicated loss of the mutant allele. Lm values (percentage of tumor cells displaying physical loss of an allele as
determined by MLPA) are represented as checked square boxes.
M. Van Heetvelde et al. / Cancer Letters 425 (2018) 125e133130second hits in BRCA1 and BRCA2 in breast and ovarian cancers from
patients with a germline BRCA1 or BRCA2 mutation. We investi-
gated the prevalence of LOH, copy number alterations, promoter
methylation and somatic point mutations at these loci. Our study
aimed at 1) uncovering whether a combination of second hits oc-
curs in BRCA1 and BRCA2-linked HBOC and 2) the weight of each of
these second hits. Quantifying these weights could prove crucial in
understanding the interplay of subclones and their effects on
therapy efﬁcacy and resistance.
In our study we scored LOH as a continuous variable based on
the percentage of tumor cells exhibiting LOH at a heterozygous
marker. In 64% of BC and 53% of OC samples Lc was <100%, meaningthat not all tumor cells displayed LOH, thought to be the predom-
inant second hit mechanism inactivating BRCA1 and BRCA2. A
recent study reported loss of theWTallele in 58/62 BC samples (30/
31 97% BRCA1, 28/31 90% BRCA2) [14]. A second study observed loss
of the functional allele in 29/39 BC (20/23 87% BRCA1, 9/16 56%
BRCA2) and 17/21 OC cases (12/15 80% BRCA1, 5/6 83% BRCA2) [15].
However therapy may inﬂuence LOH. In BRCA1-associated OC loss
of WT BRCA1 has been described to be less prevalent in tumors
treated with neoadjuvant chemotherapy (NACT) [16]. Sokolenko's
et al. [17] recent work on the response of BRCA1-associated ovarian
tumors to NACT showed the reversion of tumors with LOH to a
heterozygous state. 17/23 tumors showed LOH before NACT, but
Fig. 4. Jitter plot for methylation data. The methylation rate (metR) is depicted for every sample-probe combination. Full horizontal lines represent the maximum signal detected in
control samples (methylated control sample not included). The dashed horizontal lines represent the mean methylation detected in the replicates of the fully methylated control
sample.
M. Van Heetvelde et al. / Cancer Letters 425 (2018) 125e133 131only 5/17 tumors showed LOH after NACT. For some samples evi-
dence suggested that the reversionwas due to positive selection on
BRCA1-proﬁciency rather than reversion to the WT sequence. Our
cohort contained three BC and seven OC cases that underwent
NACT prior to resection. Two of these samples had a large LOH-free
subclone (BC_12 Lc¼ 0.63, OC_11 Lc¼ 0.67). Combined, these data
suggest that the subclone(s) with a heterozygous state can become
the predominant subclone under NACT selection. BRCA1 and BRCA2
play a vital role in homologous recombination (HR) [15,17]. It could
be hypothesized that the same will occur in ovarian (or breast)
cancers treated with PARP inhibitors. Therefore, it appears crucial
to consider at what percentage of HR-deﬁciency such therapies are
relevant and to monitor tumor development after initiating
therapy.
Remarkably, we observed a large number of samples with copy
neutral LOH; 34/45 (76%) BRCA1-associated and 7/26 (27%) BRCA2-
associated tumors displayed copy neutral LOH. Our data suggest
that copy neutral LOH occurs more frequently in BRCA1-associated
cancers, conﬁrming data of Maxwell et al. In their local cohort, 34%
(13/38) of BRCA1-associated and 23% (5/22) of BRCA2-associated
cancers displayed copy neutral LOH. They also reported that copy
neutral LOH was found in respectively 42% (23/55) and 34% (15/45)
of BRCA1-and BRCA2-associated tumors from The Cancer Genome
Atlas (TCGA) data.
Data for six BRCA1-and one BRCA2-associated BC suggest loss of
the mutant allele (Fig. 3). King et al. were the ﬁrst to describe loss of
the mutant allele in BRCA1 and BRCA2 [18]. They concluded that
LOH is a late somatic event in BRCA1 and BRCA2-linked BC devel-
opment, leading to heterogeneity in the LOH status within a tumor.
Several samples taken from both tumor cells and normal epithe-
lium displayed loss of the mutant allele, pointing out that loss of
either allele is potentially a stochastic event [18]. Two other studies
conﬁrmed these conclusions. Clarke et al. reported loss of the WT
and mutant alleles in clones taken from normal epithelial cells of
BRCA1 and BRCA2mutation carriers [19]. Martins et al. investigated
the order of loss of BRCA1, P53 and PTEN in BRCA1-associated BC
through immunohistochemistry [20]. Results showed that LOH atBRCA1 was a late/absent event in the majority of tumor lineages.
Tumors where LOH at the BRCA1 locus was the earliest event, only
displayed loss of the wild type allele in a portion of the tumor.
These data together with ours suggest that the origin of LOH in a
subclone is of a stochastic nature and the extent of LOH that is
determined at time of analysis is confounded by a history of se-
lection on each subclone in the tumor.
Consequently, inclusion of LOH-scores in BC samples in algo-
rithms to classify germline BRCA1 or BRCA2 variants of unknown
signiﬁcance (VUS) is therefore not advised, although applied in
some studies [21] Especially for the evaluation of missense variants,
such assays have been suggested to be useful. For instance, Davies
et al. found loss of the WT allele in 56/127 BC with a VUS in BRCA1
or BRCA2 [22] But using an algorithm that was designed to detect
HR-deﬁciency, only one tumor showed a high score for HR deﬁ-
ciency and concurrent loss of the wild type BRCA1 allele. It con-
cerned a tumor with the variant NM_007294.3:c.5339 T> C
(p.Leu1780Pro), a missense variant in the BRCT domain of BRCA1 for
which a deleterious effect in several functional assays has been
suggested [23,24] and considered to be pathogenic based on
segregation analysis by Yoon et al. [25].
Somatic exon-spanning gene deletions were found in several
breast and ovarian cancer samples. These deletions did not always
occur at the germline-affected locus. This again suggests that the
events leading to HR-deﬁciency in HBOC tumors are of a stochastic
nature. The occurrence of these deletions could be related to HR
deﬁciency as it is known that HR deﬁcient tumors display genomic
instability.
Methylation was investigated using MS-MLPA, targeting three
CpGs in the 50 untranslated region (UTR) of BRCA1 and ﬁve CpGs in
the 50 UTR of BRCA2. The methylation pattern across both pro-
moters clearly varies with individual CpGs, but BRCA1.2 (at position
c.-1275, relative to the BRCA1 start codon) and BRCA2.1 (at position
c.-224, relative to the BRCA2 start codon) were more frequently
methylated and both were methylated independent of the
germline-mutated gene. However, methylation ratios rarely
exceeded 20% for any probe, taking TCP into account. There may be
M. Van Heetvelde et al. / Cancer Letters 425 (2018) 125e133132methylated subclones present in some of these cancers that
contribute to the overall HR deﬁciency of the tumor. This is in
contrast to the common perception that methylation of the BRCA1
or BRCA2 promoter is a rare event in BRCA1 and BRCA2-associated
HBOC. Our data were similar to those published by Vos et al. who
used the same MS-MLPA probemix [27]. Because promoter hyper-
methylation, like other second hits, is hypothesized to offer ther-
apeutic potential (e.g. PARP inhibitors) [26,27], functional studies
arewarranted to correlate each of these CpGs' methylation status to
gene expression. In a study linking MS-MLPA data (probemix not
speciﬁed) for BRCA1 in patient-derived xenografts with BRCA1
mRNA and protein expression data, methylation ratios ranged from
60 to 100% in tumors that had little to no BRCA1 expression [28].
Somatic mutations can arise in both cancer types and could
potentially inactivate the WT allele [5,14,29,30]. In the BC samples
we observed a large number of somatic variants (n¼ 269), how-
ever, due to the quality of the FFPE samples these cannot be reliably
called (Table 1: 82.5% C:G> T:A). Indeed, based on the data pre-
sented (Supplementary Fig.1), themost important limitation of this
study was the heterogeneity within the breast cancer cohort
regarding the age of the FFPE samples. Age of the blocks showed to
have a signiﬁcant impact on the quality on the sequencing data and
the number of variants detected. In the OC samples (more recent
FFPE samples) one somatic variant was retained after ﬁltering.
These data lead us to believe that somatic point mutations in BRCA1
and BRCA2-associated HBOC are a rare second hit mechanism. A
second limitation is the manner how TCP was scored. Although it
was scored by two independent pathologists and their estimations
closely matched (mean discordance: 8± 2%), manual scoring on HE
slides was shown to exhibit observer bias [31]. This may have
inﬂuenced Lc and Lm calculations.
Although the correlation between each second hit and hormone
receptor status, grade and other histopathological and morpho-
logical features was investigated we did not obtain statistically
signiﬁcant results. This supports the hypothesis that second hits are
the result of random events, rather than the (in-)activation of
pathways, and subsequently passed on through consecutive cell
divisions.
Summarized, this study investigated all three known second hit
mechanism: LOH, hypermethylation of the promoter region and
somatic truncating mutations in both BRCA1 and BRCA2 in a cohort
of 56 breast and 15 ovarian cancer samples, all from patients with a
germline mutation in BRCA1 or BRCA2. Although most tumors
display inactivation of the WT allele of the germline-mutated gene,
combinations of second hits were detected within the same tumor
and these second hits appear to be subjected to stochastic effects
for the generation of subclones containing certain somatic alter-
ations. The survival and relative size of the molecular subclones is
then, in line with the clonal expansion cancer model, determined
by selection mechanisms. The tumor composition at any given time
holds key information about its origin and development, but even
more crucial is the information it contains about possible prognosis
and therapy effectiveness. Future cancer therapy would beneﬁt
from the initial characterization of all relevant subclones in a tumor.
Subsequent molecular monitoring of these subclones during ther-
apy will make personalized treatment tailored to each tumor's
speciﬁc biology possible, increasing treatment efﬁcacy and pre-
venting resistance.
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